Catalent, Inc. has appointed Manja Boerman, Ph.D., President, Cell & Gene Therapy, effective June 1, 2020. In this new role, Dr. Boerman will lead all of Catalent’s cell & gene therapy businesses worldwide. Dr. Boerman will continue to report to Karen Flynn, Catalent’s President of Biologics and Chief Commercial Officer.
 
Pete Buzy, who has led the Catalent Gene Therapy business since the company’s acquisition of Paragon Bioservices in May 2019, will be retiring but will remain with the company as Chairman of Catalent Gene Therapy in an advisory role for the next 12 months to support Dr. Boerman’s transition. Dr. Boerman has been leading Catalent’s cell therapy business since the acquisition of MaSTherCell in February 2020.
 

Dr. Boerman joined Catalent in December 2019 with more than 20 years’ experience in biotech and pharmaceutical services, and significant experience as a senior executive in start-up environments and global late-stage clinical development for cell therapy products. She most recently served as president of Aesica Pharmaceuticals, a UK-based CDMO, and before that as CEO for a Netherlands-based biotech and as Executive Director for Charles Rivers Laboratories where she helped open a new biologics facility in Boston.

Succeeding Dr. Boerman, Mario Gargiulo has been appointed Region President, Biologics – Europe, as well as his appointment to the company’s Executive Leadership Team. In addition to his new role, he will continue to oversee operations for all Catalent Biologics sites globally.
 
Mr. Gargiulo joined Catalent in 2017 and has held a number of leadership roles, most recently as vice president of operations, Biologics. He joined the company from Merck & Co.’s External Manufacturing organization, having previously spent most of his career at Bristol Myers Squibb in various operations leadership roles including vice president of global pharmaceutical manufacturing.